Checkpoint Therapeutics, TG Therapeutics deal

Checkpoint granted TG Therapeutics a worldwide sublicense to develop and commercialize bromodomain containing 4 (BRD4) inhibitors to treat hematological malignancies. Checkpoint will develop and commercialize the inhibitors to treat solid tumors. Checkpoint will receive a $1 million upfront licensing fee and is eligible for milestone payments up to $177 million, plus single-digit royalties. ...